These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 28606127)
1. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity. Teng Y; Cai Y; Pi W; Gao L; Shay C J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127 [TBL] [Abstract][Full Text] [Related]
2. Targeting SRC in mucinous ovarian carcinoma. Matsuo K; Nishimura M; Bottsford-Miller JN; Huang J; Komurov K; Armaiz-Pena GN; Shahzad MM; Stone RL; Roh JW; Sanguino AM; Lu C; Im DD; Rosenshien NB; Sakakibara A; Nagano T; Yamasaki M; Enomoto T; Kimura T; Ram PT; Schmeler KM; Gallick GE; Wong KK; Frumovitz M; Sood AK Clin Cancer Res; 2011 Aug; 17(16):5367-78. PubMed ID: 21737505 [TBL] [Abstract][Full Text] [Related]
3. Targeting SRC and tubulin in mucinous ovarian carcinoma. Liu T; Hu W; Dalton HJ; Choi HJ; Huang J; Kang Y; Pradeep S; Miyake T; Song JH; Wen Y; Lu C; Pecot CV; Bottsford-Miller J; Zand B; Jennings NB; Ivan C; Gallick GE; Baggerly KA; Hangauer DG; Coleman RL; Frumovitz M; Sood AK Clin Cancer Res; 2013 Dec; 19(23):6532-43. PubMed ID: 24100628 [TBL] [Abstract][Full Text] [Related]
4. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells. Wei J; Ma L; Li C; Pierson CR; Finlay JL; Lin J Curr Cancer Drug Targets; 2019; 19(7):571-582. PubMed ID: 30332965 [TBL] [Abstract][Full Text] [Related]
5. Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis. Tabariès S; Annis MG; Hsu BE; Tam CE; Savage P; Park M; Siegel PM Oncotarget; 2015 Apr; 6(11):9476-87. PubMed ID: 25823815 [TBL] [Abstract][Full Text] [Related]
6. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Ahluwalia MS; de Groot J; Liu WM; Gladson CL Cancer Lett; 2010 Dec; 298(2):139-49. PubMed ID: 20947248 [TBL] [Abstract][Full Text] [Related]
7. Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma. Lue HW; Derrick DS; Rao S; Van Gaest A; Cheng L; Podolak J; Lawson S; Xue C; Garg D; White R; Ryan CW; Drake JM; Ritz A; Heiser LM; Thomas GV Cell Rep Med; 2021 May; 2(5):100267. PubMed ID: 34095877 [TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of cannabidiol with dasatinib on lung cancer by SRC/PI3K/AKT signal pathway. Ye Q; Gui C; Jin D; Zhang J; Zhang J; Ma N; Xu L Biomed Pharmacother; 2024 Apr; 173():116445. PubMed ID: 38503236 [TBL] [Abstract][Full Text] [Related]
9. Chlorogenic Acid Inhibits Human Glioma U373 Cell Progression via Regulating the SRC/MAPKs Signal Pathway: Based on Network Pharmacology Analysis. Zhou J; Zhang F; Chen J; Zhang S; Wang H Drug Des Devel Ther; 2021; 15():1369-1383. PubMed ID: 33833498 [TBL] [Abstract][Full Text] [Related]
10. Monitoring the dynamics of Src activity in response to anti-invasive dasatinib treatment at a subcellular level using dual intravital imaging. Nobis M; McGhee EJ; Herrmann D; Magenau A; Morton JP; Anderson KI; Timpson P Cell Adh Migr; 2014; 8(5):478-86. PubMed ID: 25482620 [TBL] [Abstract][Full Text] [Related]
12. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Reynolds AR; Kyprianou N Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S144-52. PubMed ID: 16465179 [TBL] [Abstract][Full Text] [Related]
13. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Gallick GE; Corn PG; Zurita AJ; Lin SH Future Med Chem; 2012 Jan; 4(1):107-19. PubMed ID: 22168167 [TBL] [Abstract][Full Text] [Related]
14. SRC: a century of science brought to the clinic. Aleshin A; Finn RS Neoplasia; 2010 Aug; 12(8):599-607. PubMed ID: 20689754 [TBL] [Abstract][Full Text] [Related]
15. Repurposing of Antifungal Drug Flucytosine/Flucytosine Cocrystals for Anticancer Activity against Prostate Cancer Targeting Apoptosis and Inflammatory Signaling Pathways. Kanagavel M; Sparjan Samuvel RM; Ramalingam V; Nechipadappu SK Mol Pharm; 2024 May; 21(5):2577-2589. PubMed ID: 38647021 [TBL] [Abstract][Full Text] [Related]
16. Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers. Hui DHF; Tam KJ; Jiao IZF; Ong CJ Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30759745 [TBL] [Abstract][Full Text] [Related]
17. Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents. Zhang X; Haney KM; Richardson AC; Wilson E; Gewirtz DA; Ware JL; Zehner ZE; Zhang Y Bioorg Med Chem Lett; 2010 Aug; 20(15):4627-30. PubMed ID: 20579875 [TBL] [Abstract][Full Text] [Related]
18. Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy. Lu D; Chen J; Qin L; Bijou I; Yi P; Li F; Song X; MacKenzie KR; Yu X; Yang B; Roy Chowdhury S; Korp JD; O'Malley BW; Lonard DM; Wang J J Med Chem; 2024 Apr; 67(7):5333-5350. PubMed ID: 38551814 [TBL] [Abstract][Full Text] [Related]
19. Prostate tissue ablation and drug delivery by an image-guided injectable ionic liquid in ex vivo and in vivo models. Demirlenk YM; Albadawi H; Zhang Z; Atar D; Cevik E; Keum H; Kim J; Rehman S; Gunduz S; Graf E; Mayer JL; Dos Santos PR; Oklu R Sci Transl Med; 2024 Jul; 16(754):eadn7982. PubMed ID: 38959326 [TBL] [Abstract][Full Text] [Related]
20. Measurement and models accounting for cell death capture hidden variation in compound response. Bae SY; Guan N; Yan R; Warner K; Taylor SD; Meyer AS Cell Death Dis; 2020 Apr; 11(4):255. PubMed ID: 32312951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]